TY - JOUR
T1 - Potential Roles and Clinical Utility of Prebiotics in Newborns, Infants, and Children
T2 - Proceedings from a Global Prebiotic Summit Meeting, New York City, June 27-28, 2008
AU - Sherman, Philip M.
AU - Cabana, Michael
AU - Gibson, Glenn R.
AU - Koletzko, Berthold V.
AU - Neu, Josef
AU - Veereman-Wauters, Gigi
AU - Ziegler, Ekhard E.
AU - Walker, W. Allan
N1 - Funding Information:
Glenn R. Gibson, PhD, has research funding from the European Union and several food industries. None of these had any influence on the text in this article. In the past, he has served as an “ad hoc” advisor to Mead Johnson and Wyeth International Nutrition in the area of infant formulas.
Funding Information:
Ekhard E. Ziegler, MD, receives research funding from the National Institutes of Health, Abbott Nutrition, Mead Johnson Nutritionals, and Nestlé.
Funding Information:
W. Allan Walker, MD, is supported by an endowed chair in nutrition at the Harvard Medical School and by National Institutes of Health-funded grants. He has served or is serving on medical advisory boards for Abbott Nutritionals, Wyeth International Nutritionals, Mead Johnson, and Dannon/Yakult.
Funding Information:
Philip M. Sherman, MD, FRCPC, is the recipient of a Canada Research Chair in Gastrointestinal Disease. His research work has been supported by a research contract from Institut Rossell-Lallemand Inc. (Montreal, Quebec, Canada). He has served on medical advisory boards for Abbott Nutrition, Nestlé Nutrition, and Mead Johnson. Dr. Sherman also serves on the Research Advisory Board of Antibe Therapeutics and has received a medical educational contract from InSinc Consultants.
PY - 2009/11
Y1 - 2009/11
N2 - Initial bacterial colonization, including colonization with health-positive bacteria, such as bifidobacteria and lactobacilli, is necessary for the normal development of intestinal innate and adaptive immune defenses. The predominance of beneficial bacteria in the gut microflora of breast-fed infants is thought to be, at least in part, supported by the metabolism of the complex mixture of oligosaccharides present in human breast milk, and a more adult-type intestinal microbiota is found in formula-fed infants. Inadequate gut colonization, dysbiosis, may lead to an increased risk of infectious, allergic, and autoimmune disorders later in life. The addition of appropriate amounts of selected prebiotics to infant formulas can enhance the growth of bifidobacteria or lactobacilli in the colonic microbiota and, thereby, might produce beneficial effects. Among the substrates considered as prebiotics are the oligosaccharides inulin, fructo-oligosaccharides, galacto-oligosaccharides, and lactulose. There are some reports that such prebiotics have beneficial effects on various markers of health. For example, primary prevention trials in infants have provided promising data on prevention of infections and atopic dermatitis. Additional well-designed prospective clinical trials and mechanistic studies are needed to advance knowledge further in this promising field.
AB - Initial bacterial colonization, including colonization with health-positive bacteria, such as bifidobacteria and lactobacilli, is necessary for the normal development of intestinal innate and adaptive immune defenses. The predominance of beneficial bacteria in the gut microflora of breast-fed infants is thought to be, at least in part, supported by the metabolism of the complex mixture of oligosaccharides present in human breast milk, and a more adult-type intestinal microbiota is found in formula-fed infants. Inadequate gut colonization, dysbiosis, may lead to an increased risk of infectious, allergic, and autoimmune disorders later in life. The addition of appropriate amounts of selected prebiotics to infant formulas can enhance the growth of bifidobacteria or lactobacilli in the colonic microbiota and, thereby, might produce beneficial effects. Among the substrates considered as prebiotics are the oligosaccharides inulin, fructo-oligosaccharides, galacto-oligosaccharides, and lactulose. There are some reports that such prebiotics have beneficial effects on various markers of health. For example, primary prevention trials in infants have provided promising data on prevention of infections and atopic dermatitis. Additional well-designed prospective clinical trials and mechanistic studies are needed to advance knowledge further in this promising field.
UR - http://www.scopus.com/inward/record.url?scp=71749118190&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=71749118190&partnerID=8YFLogxK
U2 - 10.1016/j.jpeds.2009.08.022
DO - 10.1016/j.jpeds.2009.08.022
M3 - Article
C2 - 19840609
AN - SCOPUS:71749118190
SN - 0022-3476
VL - 155
SP - S61-S70
JO - Journal of Pediatrics
JF - Journal of Pediatrics
IS - 5
ER -